SSR128129E (also known as SSR-128129E; SSR 128129 E) is a novel, potent, orally bioavailable and allosteric FGFR1 inhibitor with potential anticancer and anti-inflammatory activity.

BLU9931 (BLU-9931; BLU 9931) is an irreversible and selective FGFR4 inhibitor with potential anticancer activity.

Futibatinib (formerly also known as TAS 120; TAS-120) is a novel, potent, irreversible and orally bioavailable inhibitor of the fibroblast growth factor receptor (FGFR) with potential anticancer activity.

Rogaratinib (formerly also known as BAY1163877; BAY-1163877) is a novel, orally available, potent and selective inhibitor of aberrant fibroblast growth factor receptor (FGFR) with anticancer activity.

FIIN-2 (FIIN 2; FIIN2) is a novel irreversible/covalent pan-FGFR inhibitor with potential anticancer activity.

PRN1371 is a highly selective, potent, covalent, and irreversible FGFR1,2,3,4 inhibitor with IC50 values of 0.6, 1.3, 4.1 and 19.3 nM, respectively.

Roblitinib (FGF-401) is a potent and highly selective inhibitor of human fibroblast growth factor receptor 4 (FGFR4) with an IC50 of 1.9 nM and with potential antineoplastic/anticancer activity.

Pemigatinib (formerly INCB054828; INCB-054828; Pemazyre) is a novel, potent, orally bioavailable and selective FGFR inhibitor with IC50 of 0.4 nM, 0.5 nM, 1.2 nM, 30 nM for FGFR1, FGFR2, FGFR3, FGFR4, respectively.

BLU-554 is a novel potent, highly-selective, and orally bioavailable inhibitor of FGFR4 (fibroblast growth factor receptor 4) with an IC50 value of 5 nM in cell free assays. BLU-554 has the potential to be used for the treatment of hepatocellular carcinoma and cholangiocarcinoma. BLU-554 is well tolerated in these tumor models. Administration of BLU-554 induces […]